Displaying drugs 2001 - 2025 of 2088 in total
Rilzabrutinib
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.[A259073, A259078]
Investigational
Bis(2,2-dimethylpropanoyloxymethyl) VK-0214
Investigational
Botaretigene sparoparvovec
Investigational
6-[18F]-Fluoro-L-m-tyrosine
Investigational
Cagrilintide
Cagrilintide is under investigation in clinical trial NCT06221969 (A Research Study to See How Much Cagrisema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor).
Investigational
Isobutyric acid
Experimental
Canoctakin
Investigational
Tildacerfont
Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring
Investigational
Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate
This solid compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. This substance targets the protein interleukin-2.
Experimental
Tavokinogene telseplasmid
Tavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.
Investigational
Mozafancogene autotemcel
RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A
Investigational
Displaying drugs 2001 - 2025 of 2088 in total